RESEARCH PAPER ANALYSIS
Case Report: Where is the boundary between autosomal recessive early-onset Parkinson's disease and dystonia-parkinsonism: a case of PLA2G6-associated neurodegeneration.
AI interpretation is pending for this paper.
EXECUTIVE SUMMARY
What the AI sees
Not AI summarized yet.
WHY IT MATTERS
Research significance
Pending deeper interpretation.
ABSTRACT
Source abstract
BACKGROUND: Mutations in the PLA2G6 gene cause a spectrum of neurodegenerative disorders, with autosomal recessive early-onset Parkinson's disease (AREP) and dystonia-parkinsonism (DP) representing the two primary subtypes of adult-onset PLA2G6-associated neurodegeneration (PLAN). CASE PRESENTATION: We report a Chinese female patient with parkinsonism caused by compound heterozygous mutations in the PLA2G6 gene. Both variants she carried-c.313G > T (p. D105Y) and c.23 T > A (p. V8D)-are novel and have not been previously reported. The patient presented with prominent parkinsonism in the upper body that responded well to dopaminergic therapy, while the lower limbs exhibited combined dystonia and a scissoring gait with poor response to dopaminergic medication. Based on the distinctive features of our case and literature review, we suggest that the traditional AREP/DP dichotomy may not fully capture the phenotypic complexity observed in PLA2G6-associated parkinsonism. CONCLUSION: This case highlights the clinical heterogeneity of PLAN and expands its genotypic spectrum with two novel mutations, suggesting that PLA2G6-related disorders may present with overlapping features of AREP and DP within the same individual.
SUPPORTING PAPER SET
32 more papers to review
1
The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity.
International immunopharmacology
91.0
2
Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications.
Cells
91.0
3
Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential.
Frontiers in pharmacology
88.0
4
Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
Neurology international
78.0
5
The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions.
Microorganisms
85.0
6
Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes.
Frontiers in clinical diabetes and healthcare
80.0
7
Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease.
Peptides
86.0
8
TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation.
Nature communications
91.5
9
Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets.
Ageing research reviews
82.0
10
Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence.
Brain, behavior, & immunity - health
80.0
11
Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases.
ChemMedChem
74.0
12
Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease.
Colloids and surfaces. B, Biointerfaces
86.0
13
Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases.
Experimental physiology
84.0
14
Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease.
Neurotoxicity research
70.0
15
Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy.
Molecular pharmaceutics
78.0
16
Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation.
Current neurovascular research
86.0
17
Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review.
Current issues in molecular biology
86.0
18
Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders.
Neuroprotection (Chichester, England)
76.0
19
Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders.
Computers in biology and medicine
65.0
20
Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets.
Experimental neurology
78.0
21
Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy.
Frontiers in pharmacology
75.2
22
Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy.
Frontiers in pharmacology
75.0
23
Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities.
Cell death discovery
82.0
24
Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions.
Frontiers in microbiology
74.0
25
Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review.
Biomolecules & biomedicine
84.0
26
Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights.
Current neurovascular research
76.0
27
Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses.
The Journal of steroid biochemistry and molecular biology
82.0
28
Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential.
Cell stress
83.3
29
Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease.
Central nervous system agents in medicinal chemistry
64.0
30
Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder.
Signal transduction and targeted therapy
84.0
31
HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches.
Inflammopharmacology
78.0
32
Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases.
Biochemical pharmacology
88.0